Melanoma Dispatch
Follow
Find tag "ASCO"
2.2K views | +1 today
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Two Array-Invented MEK Inhibitors Showcased At ASCO

"Two Array BioPharma-invented MEK inhibitors, binimetinib (MEK162) and selumetinib, were showcased at the 50th annual meeting of the American Society of Clinical Oncology (ASCO).  At the meeting, preliminary data for the combination of binimetinib and CDK4/6 inhibitor LEE011 (discovered by Novartis Institutes for BioMedical Research in collaboration with Astex Pharmaceuticals) from a Phase 1b/2 dose-escalation study conducted by Novartis in NRAS-mutant melanoma indicates the combination demonstrated an acceptable safety profile for most patients with promising preliminary antitumor activity.  Additionally, preliminary data for selumetinib showed favorable clinical activity in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PNs)."


Editor's note: This article discusses a melanoma treatment that combines two durgs: binimetinib (aka MEK162) and selumetinib. A clinical trial recently found that the combo shows promise for melanoma patients whose tumors have mutations in the NRAS gene, as detected by molecular testing. Binimetinib is also being tested as a potential treatment for patients whose tumors have mutations in the BRAF gene.

Cancer Commons's insight:

Array BioPharma  |  Jun 2, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

ASCO Releases First Three Guidelines on Cancer Survivorship Care

"The American Society of Clinical Oncology (ASCO) today issued three evidence-based clinical practice guidelines on the prevention and management of symptoms that affect many cancer survivors—neuropathy, fatigue and depression, and anxiety. The guidelines are the first three in a planned series of guidelines on survivorship care. The recommendations reinforce the need to care for the both physical and psychological needs of cancer survivors."


"The release of these guidelines come at a time when the number of people with a history of cancer in the United States has increased dramatically, from 3 million in 1971 to about 13.7 million today. Despite these important gains, cancer survivors still face a range of long-term challenges from their disease and its treatment.  Cancer survivors face an increased risk for other health problems, premature mortality and side-effects from treatment.  The transition from active treatment to post-treatment care is critical to optimal long-term health. If care is not planned and coordinated, cancer survivors are left without knowledge of their heightened risks and a follow-up plan of action.


"In addition to the guidelines, Cancer.Net, ASCO’s patient information website, has updated information for survivors that is based on ASCO’s latest recommendations."

Cancer Commons's insight:

ASCO  |  Apr 14, 2014

more...
Cancer Commons's curator insight, April 16, 4:28 PM

ASCO  |  Apr 14, 2014

Cancer Commons's curator insight, April 16, 4:28 PM

ASCO  |  Apr 14, 2014

Tambre Leighn's curator insight, April 17, 11:30 AM

Great.  More guidelines.  How much money is spent on research, writing, studies and more to get to the finding that there is a, "need to care for the both physical and psychological needs of cancer survivors."  At some point, information must be turned into action - and many recommendations in survivorship these days come with mandates but no resources to implement or processes by which to initiate.


Cancer survivorship needs more funding and more insurance coverage, not more recommendations  - most of which have already been well documented and published for over a decade.  

Rescooped by Cancer Commons from Lung Cancer Dispatch
Scoop.it!

ASCO Sets Up Framework to Improve Cancer Care

ASCO Sets Up Framework to Improve Cancer Care | Melanoma Dispatch | Scoop.it

"A new report, published by the American Society of Clinical Oncology (ASCO) in the Journal of Oncology Practice and presented in part via a live Webcast in Washington, DC, outlined the current and future challenges of cancer care in the United States. An increasing cost of care and demand for quality care, growing cancer patient and cancer survivor populations, and a decreasing oncology workforce are all contributing to a challenging environment for cancer care."

Cancer Commons's insight:

Cancer Network  |  Mar 19, 2014

more...
Cancer Commons's curator insight, March 20, 1:55 PM

Cancer Network  |  Mar 19, 2014

Cancer Commons's curator insight, March 20, 1:56 PM

Cancer Network  |  Mar 19, 2014

Scooped by Cancer Commons
Scoop.it!

Drug Targets Two Common Melanoma Mutations

An experimental drug could help control some melanomas that have BRAF or NRAS mutations, according to a report at an American Society of Clinical Oncology meeting. Tumors shrank or did not get worse in 8 out of 35 patients with the most common BRAF mutation (V600E), and in 6 out of 28 patients with NRAS mutations. This is the first targeted treatment for melanomas that have NRAS mutations. BRAF and NRAS mutations can activate a protein called MEK that is involved in cell division. The experimental drug, which is called MEK162, is a MEK inhibitor. The side effects of MEK162, which included diarrhea, rashes and swelling, were manageable.

Cancer Commons's insight:

MedPage Today | Jun 8, 2012

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New Therapies Harness Power of the Immune System Against Cancer

New Therapies Harness Power of the Immune System Against Cancer | Melanoma Dispatch | Scoop.it

"New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). These treatments – used alone or in combination – fight cancer by activating and amplifying the body's immune response to the disease.


"The new studies find high activity with investigative drugs for advanced melanoma, and show for the first time that ipilimumab, a treatment already approved for advanced melanoma, can substantially decrease the risk of melanoma recurrence in certain patients with earlier-stage disease. In addition, another small trial reports that a one-time, personalized immunotherapy treatment induces complete and long-lasting remissions in a small number of women with advanced cervical cancer – a disease with little to no effective treatment options."


Editor's note: Immunotherapies are treatments that boost a patient's own immune system to fight cancer. Learn more.

Cancer Commons's insight:

Medical Xpress  |  Jun 2, 2014

more...
No comment yet.
Rescooped by Cancer Commons from Lung Cancer Dispatch
Scoop.it!

ASCO: ‘Smaller, Smarter’ Cancer Trials Will Yield More Meaningful Results

ASCO: ‘Smaller, Smarter’ Cancer Trials Will Yield More Meaningful Results | Melanoma Dispatch | Scoop.it

"ASCO recently released new recommendations designed to increase the likelihood of 'clinical meaningful outcomes' in trials for advanced pancreatic, lung, breast and colon cancers.


"The recommendations — developed by the ASCO Cancer Research Committee in conjunction with other experts and patient advocates, and published in the Journal of Clinical Oncology — establish OS goals for clinical trial designs that are intended to significantly extend the lives of people with cancer."

Cancer Commons's insight:

Healio  |  Mar 23, 2014

more...
Cancer Commons's curator insight, March 24, 8:25 PM

Healio  |  Mar 23, 2014

Cancer Commons's curator insight, March 25, 12:57 PM

Healio  |  Mar 23, 2014

Rescooped by Cancer Commons from Lung Cancer Dispatch
Scoop.it!

Research Achieves Significant Progress in the Fight Against Cancer

Research Achieves Significant Progress in the Fight Against Cancer | Melanoma Dispatch | Scoop.it

A report released by the American Society of Clinical Oncology (ASCO) emphasizes the noteworthy progress made in the understanding and treatment of cancer in recent years. Cancer death rates have declined 21% among men and 12% among women since the 1990s. A better understanding of the genetic makeup of different cancers helps guide individualized treatment. Research has also yielded first-ever therapies for several treatment-resistant cancers. Targeted immunotherapy lets patients harness their own immune system to fight their cancer. However, due to a growing and aging population, new cancer cases in the U.S. are predicted to increase 40% by 2030. The report’s authors warn that stagnant funding in the wake of federal budget cuts could stall further advances in cancer research.

Cancer Commons's insight:

ScienceDaily  |  Dec 11, 2013

more...
Cancer Commons's curator insight, December 13, 2013 4:29 AM

ScienceDaily  |  Dec 11, 2013

Cancer Commons's curator insight, December 13, 2013 2:32 PM

ScienceDaily  |  Dec 11, 2013

Scooped by Cancer Commons
Scoop.it!

Dabrafenib Bests Chemotherapy and May be Safer than Vemurafenib

A clinical trial found that dabrafenib, a BRAF inhibitor, was far more effective in treating melanomas that have BRAF mutations than the chemotherapy drug dacarbazine, according to a report at an American Society of Clinical Oncology meeting. Patients treated with this drug lived without getting worse for 70% longer than those treated with dacarbazine (5.1 vs. 2.7 months, respectively). Moreover, compared to those treated with vemurafenib in other studies, dabrafenib-treated patients had less risk of another kind of skin cancer called squamous cell carcinoma. This suggests that dabrafenib, which is experimental, could be safer than vemurafenib, which is FDA approved.

Cancer Commons's insight:

MedPage Today | Jun 4, 2012

more...
No comment yet.